Diagnostic biomarker firm KineMed said this week that it has signed a deal to provide its translational biomarker platform to Isis Pharmaceuticals and CHDI Foundation for use in their partnership developing an antisense-based treatment for Huntington's disease.
"A pharmacodynamic biomarker could be an important contribution to our clinical development efforts,” Frank Bennett, senior vice president of research at Isis, said in a statement.
Specific terms of the arrangement were not disclosed.